Europe Non-Invasive Prenatal Testing Market

Europe Non-Invasive Prenatal Testing Market Size (2023 to 2028)

The size of the Europe Non-Invasive Prenatal Testing Market Size is valued at USD 0.60 Billion in 2023 and is projected to grow at a CAGR of 15.3%, to touch USD 1.22 Billion in 2028.

Non-invasive prenatal testing (NIPT) is a DNA test of maternal blood to detect pregnancies for the most common fetal chromosomal abnormalities, such as trisomy 21, Down syndrome, and Edwards’s trisomy 18, and Patau trisomy 13 syndromes. While NIPT can also determine the sex of the fetus, NIPT is very reliable in over 99% of Down syndrome cases. According to Eurostat, in 2019, around 47% of women in the European Union who gave birth to their first child were in the average age group of 28.4 years. Besides, in the same year, approximately 82,372 births to the first child were reported to women over 45 years of age. In England, the average age of new mothers fell from 28.6 years in 2016 to 29.4 years in 2019. In June 2020, BGI Genomics launched the NIFTY test with Eluthia, under the brand name Previa Test in Germany with a sensitivity rate greater than 99% to expand access and increase sales of non-invasive products in Germany.

The European market is driven by several factors, such as the high incidence rate of babies born with Down syndrome, the lack of risk of miscarriage with the NIPT test, the change in maternity trend to an advanced age of the mother (33 years and over), an increasing emphasis on reimbursement for NIPT and a growing preference for non-invasive techniques over invasive methods. As technology develops and the cost of genetic testing declines, researchers are hopeful that the market for non-invasive prenatal testing can be obtained for many other genetic diseases. As the non-invasive prenatal testing market is available in more and more fields, significant business momentum is expected to drive the market growth in the forecast years. Many healthcare professionals believe that the market for non-invasive prenatal testing can be implemented in routine prenatal care. Growing popularity among pregnant women as a safer alternative to amniocentesis and awareness of prenatal genetic issues drives non-invasive prenatal testing. Due to the increasing incidence of miscarriages and complications, non-invasive prenatal testing is expected to lead significant market shares.

Despite the changing trend and adoption of non-invasive prenatal testing, the market faces challenges as the government enforces strict regulations. Under these regulations, manufacturing companies must follow standardized rules to maintain test accuracy and deliver quality medical devices. Besides, these regulatory procedures are time-consuming and hamper the rapid development and innovation of devices, making it difficult for the market to grow.

This research report on the European Non-Invasive Prenatal Testing Market has been segmented and sub-segmented into the following categories:

• By Instruments: Ultrasound, NGS, PCR, and Microarray
• By Method: FCMB and Cf-DNA
• By Application: Trisomy, Microdeletion, Genetics and Rh Factor
• By End User: Hospitals and Diagnostic Labs
• By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic, and Rest of Europe

Companies playing a dominant role in the Europe Non-Invasive Prenatal Testing Market profiled in this report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China)